



Profile

Name: Gameet (Microsemina SA)  
Sector: Medical Devices  
Start Date: 29/09/2023  
Number of People on the Team: 3  
(Founders and Manager)

Metrics

Investment up to the moment:  
USD 4,000 (Research Grant)  
**USD 250,000** SF500 (Life SciencesVC)  
USD 25,000 Government Grant

Next Rounds

We are raising \$1.65M in 3 phases,  
divided into strategic milestones: 2 for  
clinical validation (\$955,000) 3Q25 and  
1Q26, and 1 for FDA submission and  
market entry 3Q26 (\$700,000)

Team



Maximiliano Tourmente  
CEO, Founding Partner  
PhD Biological Sciences  
Sperm physiology, bioenergetics



Héctor Alejandro Guidobaldi  
CSO/CTO, Founding Partner  
PhD Biological Sciences  
Device design, 3-D printing



Fernando Cardiello  
CBDO  
MBA, Bachelor in Economics  
M&A, entrepreneur

Contact

Web: <https://www.gameet.life>



<https://www.linkedin.com/company/gameetlife>

Héctor Alejandro Guidobaldi  
[guidobaldi@gmail.com](mailto:guidobaldi@gmail.com)

Maximiliano Tourmente  
[maxitour@gmail.com](mailto:maxitour@gmail.com)

Fernando Cardiello  
[fernandocardiello@gmail.com](mailto:fernandocardiello@gmail.com)

Tweet Pitch


Our business is to optimize the production of healthy human embryos through self-functioning easy-to-use device

Problem, opportunity & necessity

Infertility affects 1 in 6 couples worldwide. Annually, more than 4 million assisted reproduction treatments (ARTs) are performed. However, due to the low efficacy of the current techniques, only 1 in 4 cycles end with a full-term baby (25%). Therefore, patients are forced to undergo treatment multiple times, with the consequent economic and emotional costs.

Solution

MicroIVF is an *in-vitro* fertilization device in which gamete preparation and fertilization occur in a single step, rather than in separate and sequential manual steps as in traditional ARTs. Importantly, it also includes sperm selection and maturation capabilities that increase embryo quality. MicroIVF offers standardization and reduction in procedure costs while increasing efficiency, consistency, and accessibility.



Customers and users

Our customers are fertility clinics, hospitals, and other healthcare institutions that perform ARTs. Our devices will be used by fertility specialists and embryologists. Patients who undergo these treatments will be the final beneficiaries of our devices.

Value proposition statement

Gameet develops standardized and simple-to-use embryo production systems for fertility clinics and hospitals. Our devices reduce the manipulation of embryos and increase their quality, resulting in higher birth rates after ART.

Intellectual Property (IP) and Regulation

We have already filed the patent in Argentina. Our strategy is to initiate the PCT process in June, followed by national phase filings in the EU, USA, and Brazil. MicroIVF falls under Class II (ex vivo) medical devices according to FDA (USA) and EMA (EU) regulations. Once FDA approval is obtained, we will proceed with registrations in other agencies.

Market

Approximately 4 million high-complexity ART cycles were carried out last year around the world at 10.000 USD per treatment. This represents an annual TAM of USD 3.6 B for our devices, which can be captured without incurring extra costs for fertility centers. Approximately 50% of our TAM is located in developed, western economies (SAM). A penetration of 50% of the SAM is likely to be achieved within 6 years under the most likely scenario.

Go to market strategy and action plan

Our business model is B2B, and microFIV will be sold as a disposable device. We are currently advancing our preclinical tests in animal models and have already secured the collaboration of 4 reproduction centers to engage in clinical tests in humans. We will seek FDA class II approval and submit a 510k application to access the US market.

